View ValuationCofinimmo 향후 성장Future 기준 점검 1/6Cofinimmo 의 수익은 연간 0.6% 감소할 것으로 예상되는 반면, 연간 수익은 7.6% 로 증가할 것으로 예상됩니다. EPS는 연간 8.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 6.9% 로 예상됩니다.핵심 정보7.6%이익 성장률8.42%EPS 성장률Health Care REITs 이익 성장0%매출 성장률-0.6%향후 자기자본이익률6.88%애널리스트 커버리지Good마지막 업데이트01 Jun 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Director Mrics Gielens was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Mar 10Cofinimmo SA(ENXTBR:COFB) dropped from Brussels BEL 20 IndexCofinimmo SA removed공시 • Oct 03+ 4 more updatesCofinimmo SA to Report Nine Months, 2026 Results on Oct 23, 2026Cofinimmo SA announced that they will report nine months, 2026 results on Oct 23, 2026공시 • May 15Cofinimmo SA announces Annual dividend, payable on May 22, 2025Cofinimmo SA announced Annual dividend of EUR 4.3400 per share payable on May 22, 2025, ex-date on May 20, 2025 and record date on May 21, 2025.Reported Earnings • Oct 27Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €85.3m (down 5.3% from 3Q 2023). Net loss: €274.0k (down 102% from profit in 3Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 2.6% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 43 percentage points per year, which is a significant difference in performance.Reported Earnings • Jul 28Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €87.9m (down 2.5% from 2Q 2023). Net income: €24.6m (up 155% from 2Q 2023). Profit margin: 28% (up from 11% in 2Q 2023). Revenue is expected to decline by 1.6% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 1.9%.공시 • Jul 26+ 4 more updatesCofinimmo SA to Report Q3, 2025 Results on Oct 31, 2025Cofinimmo SA announced that they will report Q3, 2025 results Pre-Market on Oct 31, 2025Declared Dividend • May 12Dividend of €4.34 announcedShareholders will receive a dividend of €4.34. Ex-date: 13th May 2024 Payment date: 3rd June 2024 Dividend yield will be 6.5%, which is higher than the industry average of 3.8%.Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: €0.48 (vs €0.53 in 1Q 2023)First quarter 2024 results: EPS: €0.48 (down from €0.53 in 1Q 2023). Revenue: €87.0m (up 2.4% from 1Q 2023). Net income: €17.5m (flat on 1Q 2023). Profit margin: 20% (in line with 1Q 2023). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 2.0%. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.Reported Earnings • Apr 08Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022)Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €389.0m (up 5.8% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 2.9%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 26Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022)Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €349.0m (down 5.1% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.Buying Opportunity • Jan 17Now 20% undervaluedOver the last 90 days, the stock is up 26%. The fair value is estimated to be €89.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 0.9% per annum. Earnings is also forecast to grow by 48% per annum over the same time period.공시 • Oct 28+ 5 more updatesCofinimmo SA to Report First Half, 2024 Results on Jul 26, 2024Cofinimmo SA announced that they will report first half, 2024 results on Jul 26, 2024Reported Earnings • Oct 28Third quarter 2023 earnings released: EPS: €0.34 (vs €4.60 in 3Q 2022)Third quarter 2023 results: EPS: €0.34 (down from €4.60 in 3Q 2022). Revenue: €83.1m (up 5.9% from 3Q 2022). Net income: €11.4m (down 92% from 3Q 2022). Profit margin: 14% (down from 189% in 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.공시 • Oct 07Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million.Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million. Security Name: Shares Security Type: Common Stock Securities Offered: 2,785,805 Price\Range: €60 Transaction Features: Rule 144A공시 • Sep 27An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million.An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million on September 25, 2023.New Risk • Jul 31New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 49% Last year net profit margin: 137% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.5% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (49% net profit margin). Shareholders have been diluted in the past year (5.4% increase in shares outstanding).Reported Earnings • Jul 30Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €85.3m (up 1.2% from 2Q 2022). Net income: €9.64m (down 94% from 2Q 2022). Profit margin: 11% (down from 187% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 30Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €85.3m (up 1.2% from 2Q 2022). Net income: €9.64m (down 94% from 2Q 2022). Profit margin: 11% (down from 187% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.New Risk • Jul 28New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 101% Dividend yield: 8.7% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.2% operating cash flow to total debt). Minor Risks Dividend is not well covered by cash flows (101% cash payout ratio). Large one-off items impacting financial results. Shareholders have been diluted in the past year (7.2% increase in shares outstanding).공시 • Jul 14Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home for € 7.35 million.Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home on for €7.35 million July 13, 2023.Cofinimmo SA (ENXTBR:COFB) completed the acquisition of The Park Nursing Home on July 13, 2023.Buying Opportunity • May 15Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 10%. The fair value is estimated to be €100, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 1.7% per annum. Earnings is also forecast to grow by 6.6% per annum over the same time period.Upcoming Dividend • May 08Upcoming dividend of €4.34 per share at 7.2% yieldEligible shareholders must have bought the stock before 15 May 2023. Payment date: 17 May 2023. Trailing yield: 7.2%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (6.2%).Buying Opportunity • Apr 25Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €106, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 0.7% per annum. Earnings is forecast to decline by 10% per annum over the same time period.Reported Earnings • Apr 11Full year 2022 earnings released: EPS: €15.09 (vs €8.78 in FY 2021)Full year 2022 results: EPS: €15.09 (up from €8.78 in FY 2021). Revenue: €325.1m (down 5.2% from FY 2021). Net income: €482.9m (up 86% from FY 2021). Net asset value (NAV) per share: €118 (up 15% from FY 2021). The current share price is 29% lower than NAV per share. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Buying Opportunity • Mar 24Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 5.2%. The fair value is estimated to be €98.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 4.4% per annum. Earnings is forecast to decline by 10% per annum over the same time period.Buying Opportunity • Mar 03Now 22% undervaluedOver the last 90 days, the stock is up 1.1%. The fair value is estimated to be €107, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 4.9% per annum. Earnings is forecast to decline by 11% per annum over the same time period.Reported Earnings • Feb 22Full year 2022 earnings released: EPS: €15.09 (vs €8.78 in FY 2021)Full year 2022 results: EPS: €15.09 (up from €8.78 in FY 2021). Revenue: €325.1m (down 5.2% from FY 2021). Net income: €482.9m (up 86% from FY 2021). Net asset value (NAV) per share: €118 (flat on FY 2021). The current share price is 27% lower than NAV per share. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Buying Opportunity • Feb 07Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €108, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 5.3% per annum. Earnings is also forecast to grow by 0.09% per annum over the same time period.Reported Earnings • Oct 30Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €76.6m (up 6.2% from 3Q 2021). Net income: €148.3m (up 103% from 3Q 2021). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the REITs industry in Europe.Reported Earnings • Jul 30Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €79.4m (up 7.6% from 2Q 2021). Net income: €157.6m (up 213% from 2Q 2021). Over the next year, revenue is forecast to decline by 3.0% while the industry in Germany is not expected to grow.공시 • Jul 30+ 4 more updatesCofinimmo SA to Report Fiscal Year 2022 Final Results on Apr 07, 2023Cofinimmo SA announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Apr 07, 2023Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Michael Zahn was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • May 09Upcoming dividend of €4.20 per shareEligible shareholders must have bought the stock before 16 May 2022. Payment date: 18 May 2022. Trailing yield: 4.9%. Within top quartile of German dividend payers (4.2%). Higher than average of industry peers (4.4%).Reported Earnings • May 01First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: €79.2m (up 12% from 1Q 2021). Net income: €167.0m (up 271% from 1Q 2021). Over the next year, revenue is forecast to decline by 4.3% while the industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 5% per year.Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 10Full year 2021 earnings released: EPS: €8.77 (vs €4.50 in FY 2020)Full year 2021 results: EPS: €8.77 (up from €4.50 in FY 2020). Revenue: €302.0m (up 3.2% from FY 2020). Net income: €260.0m (up 118% from FY 2020). Profit margin: 86% (up from 41% in FY 2020). The increase in margin was primarily driven by lower expenses. Over the next year, revenue is forecast to grow 8.6% while the reits industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 4% per year and the company’s share price has also increased by 4% per year.Reported Earnings • Feb 25Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: €8.22 (up from €4.50 in FY 2020). Revenue: €299.6m (up 2.3% from FY 2020). Net income: €260.3m (up 118% from FY 2020). Profit margin: 87% (up from 41% in FY 2020). Revenue missed analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 12% while thereits industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat.공시 • Dec 18Cofinimmo SA (ENXTBR:COFB) acquired Hof van Blom from Nijhuis Bouw B.V. for €13 million.Cofinimmo SA (ENXTBR:COFB) acquired Hof van Blom from Nijhuis Bouw B.V. for €13 million on December 16, 2021. Cofinimmo SA (ENXTBR:COFB) completed the acquisition of Hof van Blom from Nijhuis Bouw B.V. on December 16, 2021.Reported Earnings • Oct 29Third quarter 2021 earnings released: EPS €2.44 (vs €1.45 in 3Q 2020)Third quarter 2021 results: Revenue: €72.6m (up 123% from 3Q 2020). Net income: €73.1m (up 87% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Upcoming Dividend • May 10Upcoming dividend of €4.06 per shareEligible shareholders must have bought the stock before 17 May 2021. Payment date: 19 May 2021. Trailing yield: 4.6%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (3.5%).Reported Earnings • Apr 30First quarter 2021 earnings released: EPS €1.67 (vs €1.64 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €71.0m (down 20% from 1Q 2020). Net income: €45.1m (up 6.9% from 1Q 2020). Profit margin: 64% (up from 48% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Reported Earnings • Apr 12Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €292.7m (up 2.6% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 41% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Reported Earnings • Feb 28Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €259.2m (down 9.2% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 46% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Feb 28Revenue beats expectationsRevenue exceeded analyst estimates by 3.3%. Over the next year, revenue is expected to shrink by 1.1% compared to a 47% growth forecast for the REITs industry in Germany.Is New 90 Day High Low • Feb 11New 90-day high: €130The company is up 1.0% from its price of €129 on 12 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €152 per share.Reported Earnings • Jan 17Third quarter 2020 earnings released: EPS €1.45Third quarter 2020 results: Revenue: €32.5m (up 9.0% from 3Q 2019). Net income: €39.2m (down 37% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 5% per year.Reported Earnings • Nov 21Third quarter 2020 earnings released: EPS €1.45Third quarter 2020 results: Revenue: €32.5m (down 52% from 3Q 2019). Net income: €39.2m (down 37% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 6% per year.Is New 90 Day High Low • Oct 29New 90-day low: €117The company is down 4.0% from its price of €122 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the REITs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €136 per share.Is New 90 Day High Low • Oct 05New 90-day high: €129The company is up 5.0% from its price of €123 on 07 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the REITs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €135 per share.Is New 90 Day High Low • Sep 20New 90-day high: €128The company is up 2.0% from its price of €126 on 22 June 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €133 per share.이익 및 매출 성장 예측DB:COF - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202838225589N/A312/31/2027369237105N/A712/31/2026356229123N/A23/31/2026383203N/AN/AN/A12/31/2025382213297297N/A9/30/2025390192N/AN/AN/A6/30/2025391134288288N/A3/31/2025392111N/AN/AN/A12/31/202439264279279N/A9/30/2024392-52N/AN/AN/A6/30/2024392-41254255N/A3/31/2024391-55N/AN/AN/A12/31/2023389-55227228N/A9/30/202337949N/AN/AN/A6/30/2023379185223224N/A3/31/2023373333N/AN/AN/A12/31/2022368483209210N/A9/30/2022367565N/AN/AN/A6/30/2022357489205206N/A3/31/2022351382N/AN/AN/A12/31/2021343260199200N/A9/30/2021328189N/AN/AN/A6/30/2021312155185186N/A3/31/2021276122N/AN/AN/A12/31/2020293119178180N/A9/30/2020296170N/AN/AN/A6/30/2020266193166167N/A3/31/2020292222N/AN/AN/A12/31/2019285205N/A169N/A9/30/2019241134N/AN/AN/A6/30/2019270119N/A182N/A3/31/2019259105N/AN/AN/A12/31/2018263146N/A161N/A9/30/2018260186N/AN/AN/A6/30/2018258170N/A140N/A3/31/2018264166N/AN/AN/A12/31/2017263137N/A157N/A9/30/2017267121N/AN/AN/A6/30/2017267128N/A168N/A3/31/2017275134N/AN/AN/A12/31/201625797N/A144N/A9/30/2016253100N/AN/AN/A6/30/201625582N/A148N/A3/31/2016249110N/AN/AN/A12/31/2015255104N/A170N/A9/30/201526076N/AN/AN/A6/30/201526266N/A158N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: COF 의 연간 예상 수익 증가율(7.6%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: COF 의 연간 수익(7.6%)이 German 시장(17.2%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: COF 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: COF 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -0.6%).고성장 매출: COF 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -0.6%).주당순이익 성장 예측향후 자기자본이익률미래 ROE: COF의 자본 수익률은 3년 후 6.9%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YReal-estate 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/11 07:39종가2026/06/11 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cofinimmo SA는 19명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Celine HuynhBarclaysKai KloseBerenbergRobert JonesBNP Paribas16명의 분석가 더 보기
Board Change • May 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Director Mrics Gielens was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Oct 03+ 4 more updatesCofinimmo SA to Report Nine Months, 2026 Results on Oct 23, 2026Cofinimmo SA announced that they will report nine months, 2026 results on Oct 23, 2026
공시 • May 15Cofinimmo SA announces Annual dividend, payable on May 22, 2025Cofinimmo SA announced Annual dividend of EUR 4.3400 per share payable on May 22, 2025, ex-date on May 20, 2025 and record date on May 21, 2025.
Reported Earnings • Oct 27Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €85.3m (down 5.3% from 3Q 2023). Net loss: €274.0k (down 102% from profit in 3Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 2.6% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 43 percentage points per year, which is a significant difference in performance.
Reported Earnings • Jul 28Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €87.9m (down 2.5% from 2Q 2023). Net income: €24.6m (up 155% from 2Q 2023). Profit margin: 28% (up from 11% in 2Q 2023). Revenue is expected to decline by 1.6% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 1.9%.
공시 • Jul 26+ 4 more updatesCofinimmo SA to Report Q3, 2025 Results on Oct 31, 2025Cofinimmo SA announced that they will report Q3, 2025 results Pre-Market on Oct 31, 2025
Declared Dividend • May 12Dividend of €4.34 announcedShareholders will receive a dividend of €4.34. Ex-date: 13th May 2024 Payment date: 3rd June 2024 Dividend yield will be 6.5%, which is higher than the industry average of 3.8%.
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: €0.48 (vs €0.53 in 1Q 2023)First quarter 2024 results: EPS: €0.48 (down from €0.53 in 1Q 2023). Revenue: €87.0m (up 2.4% from 1Q 2023). Net income: €17.5m (flat on 1Q 2023). Profit margin: 20% (in line with 1Q 2023). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 2.0%. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.
Reported Earnings • Apr 08Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022)Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €389.0m (up 5.8% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to grow by 2.9%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 26Full year 2023 earnings released: €1.63 loss per share (vs €15.09 profit in FY 2022)Full year 2023 results: €1.63 loss per share (down from €15.09 profit in FY 2022). Revenue: €349.0m (down 5.1% from FY 2022). Net loss: €55.5m (down 112% from profit in FY 2022). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.
Buying Opportunity • Jan 17Now 20% undervaluedOver the last 90 days, the stock is up 26%. The fair value is estimated to be €89.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 0.9% per annum. Earnings is also forecast to grow by 48% per annum over the same time period.
공시 • Oct 28+ 5 more updatesCofinimmo SA to Report First Half, 2024 Results on Jul 26, 2024Cofinimmo SA announced that they will report first half, 2024 results on Jul 26, 2024
Reported Earnings • Oct 28Third quarter 2023 earnings released: EPS: €0.34 (vs €4.60 in 3Q 2022)Third quarter 2023 results: EPS: €0.34 (down from €4.60 in 3Q 2022). Revenue: €83.1m (up 5.9% from 3Q 2022). Net income: €11.4m (down 92% from 3Q 2022). Profit margin: 14% (down from 189% in 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
공시 • Oct 07Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million.Cofinimmo SA has completed a Follow-on Equity Offering in the amount of €167.1483 million. Security Name: Shares Security Type: Common Stock Securities Offered: 2,785,805 Price\Range: €60 Transaction Features: Rule 144A
공시 • Sep 27An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million.An unknown buyer signed a private agreement to acquire Two Nursing And Care Homes In Belgium from Cofinimmo SA (ENXTBR:COFB) for €31 million on September 25, 2023.
New Risk • Jul 31New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 49% Last year net profit margin: 137% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.5% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (49% net profit margin). Shareholders have been diluted in the past year (5.4% increase in shares outstanding).
Reported Earnings • Jul 30Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €85.3m (up 1.2% from 2Q 2022). Net income: €9.64m (down 94% from 2Q 2022). Profit margin: 11% (down from 187% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 30Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €85.3m (up 1.2% from 2Q 2022). Net income: €9.64m (down 94% from 2Q 2022). Profit margin: 11% (down from 187% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
New Risk • Jul 28New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 101% Dividend yield: 8.7% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.2% operating cash flow to total debt). Minor Risks Dividend is not well covered by cash flows (101% cash payout ratio). Large one-off items impacting financial results. Shareholders have been diluted in the past year (7.2% increase in shares outstanding).
공시 • Jul 14Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home for € 7.35 million.Cofinimmo SA (ENXTBR:COFB) acquired The Park Nursing Home on for €7.35 million July 13, 2023.Cofinimmo SA (ENXTBR:COFB) completed the acquisition of The Park Nursing Home on July 13, 2023.
Buying Opportunity • May 15Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 10%. The fair value is estimated to be €100, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 1.7% per annum. Earnings is also forecast to grow by 6.6% per annum over the same time period.
Upcoming Dividend • May 08Upcoming dividend of €4.34 per share at 7.2% yieldEligible shareholders must have bought the stock before 15 May 2023. Payment date: 17 May 2023. Trailing yield: 7.2%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (6.2%).
Buying Opportunity • Apr 25Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €106, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 0.7% per annum. Earnings is forecast to decline by 10% per annum over the same time period.
Reported Earnings • Apr 11Full year 2022 earnings released: EPS: €15.09 (vs €8.78 in FY 2021)Full year 2022 results: EPS: €15.09 (up from €8.78 in FY 2021). Revenue: €325.1m (down 5.2% from FY 2021). Net income: €482.9m (up 86% from FY 2021). Net asset value (NAV) per share: €118 (up 15% from FY 2021). The current share price is 29% lower than NAV per share. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Buying Opportunity • Mar 24Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 5.2%. The fair value is estimated to be €98.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 4.4% per annum. Earnings is forecast to decline by 10% per annum over the same time period.
Buying Opportunity • Mar 03Now 22% undervaluedOver the last 90 days, the stock is up 1.1%. The fair value is estimated to be €107, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 4.9% per annum. Earnings is forecast to decline by 11% per annum over the same time period.
Reported Earnings • Feb 22Full year 2022 earnings released: EPS: €15.09 (vs €8.78 in FY 2021)Full year 2022 results: EPS: €15.09 (up from €8.78 in FY 2021). Revenue: €325.1m (down 5.2% from FY 2021). Net income: €482.9m (up 86% from FY 2021). Net asset value (NAV) per share: €118 (flat on FY 2021). The current share price is 27% lower than NAV per share. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Buying Opportunity • Feb 07Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €108, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 33%. For the next 3 years, revenue is forecast to grow by 5.3% per annum. Earnings is also forecast to grow by 0.09% per annum over the same time period.
Reported Earnings • Oct 30Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €76.6m (up 6.2% from 3Q 2021). Net income: €148.3m (up 103% from 3Q 2021). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the REITs industry in Europe.
Reported Earnings • Jul 30Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €79.4m (up 7.6% from 2Q 2021). Net income: €157.6m (up 213% from 2Q 2021). Over the next year, revenue is forecast to decline by 3.0% while the industry in Germany is not expected to grow.
공시 • Jul 30+ 4 more updatesCofinimmo SA to Report Fiscal Year 2022 Final Results on Apr 07, 2023Cofinimmo SA announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Apr 07, 2023
Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Michael Zahn was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • May 09Upcoming dividend of €4.20 per shareEligible shareholders must have bought the stock before 16 May 2022. Payment date: 18 May 2022. Trailing yield: 4.9%. Within top quartile of German dividend payers (4.2%). Higher than average of industry peers (4.4%).
Reported Earnings • May 01First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: €79.2m (up 12% from 1Q 2021). Net income: €167.0m (up 271% from 1Q 2021). Over the next year, revenue is forecast to decline by 4.3% while the industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 5% per year.
Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Benoit Graulich was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 10Full year 2021 earnings released: EPS: €8.77 (vs €4.50 in FY 2020)Full year 2021 results: EPS: €8.77 (up from €4.50 in FY 2020). Revenue: €302.0m (up 3.2% from FY 2020). Net income: €260.0m (up 118% from FY 2020). Profit margin: 86% (up from 41% in FY 2020). The increase in margin was primarily driven by lower expenses. Over the next year, revenue is forecast to grow 8.6% while the reits industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 4% per year and the company’s share price has also increased by 4% per year.
Reported Earnings • Feb 25Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: €8.22 (up from €4.50 in FY 2020). Revenue: €299.6m (up 2.3% from FY 2020). Net income: €260.3m (up 118% from FY 2020). Profit margin: 87% (up from 41% in FY 2020). Revenue missed analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 12% while thereits industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat.
공시 • Dec 18Cofinimmo SA (ENXTBR:COFB) acquired Hof van Blom from Nijhuis Bouw B.V. for €13 million.Cofinimmo SA (ENXTBR:COFB) acquired Hof van Blom from Nijhuis Bouw B.V. for €13 million on December 16, 2021. Cofinimmo SA (ENXTBR:COFB) completed the acquisition of Hof van Blom from Nijhuis Bouw B.V. on December 16, 2021.
Reported Earnings • Oct 29Third quarter 2021 earnings released: EPS €2.44 (vs €1.45 in 3Q 2020)Third quarter 2021 results: Revenue: €72.6m (up 123% from 3Q 2020). Net income: €73.1m (up 87% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Upcoming Dividend • May 10Upcoming dividend of €4.06 per shareEligible shareholders must have bought the stock before 17 May 2021. Payment date: 19 May 2021. Trailing yield: 4.6%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (3.5%).
Reported Earnings • Apr 30First quarter 2021 earnings released: EPS €1.67 (vs €1.64 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €71.0m (down 20% from 1Q 2020). Net income: €45.1m (up 6.9% from 1Q 2020). Profit margin: 64% (up from 48% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Reported Earnings • Apr 12Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €292.7m (up 2.6% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 41% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 28Full year 2020 earnings released: EPS €4.50 (vs €8.37 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €259.2m (down 9.2% from FY 2019). Net income: €119.2m (down 42% from FY 2019). Profit margin: 46% (down from 72% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Feb 28Revenue beats expectationsRevenue exceeded analyst estimates by 3.3%. Over the next year, revenue is expected to shrink by 1.1% compared to a 47% growth forecast for the REITs industry in Germany.
Is New 90 Day High Low • Feb 11New 90-day high: €130The company is up 1.0% from its price of €129 on 12 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €152 per share.
Reported Earnings • Jan 17Third quarter 2020 earnings released: EPS €1.45Third quarter 2020 results: Revenue: €32.5m (up 9.0% from 3Q 2019). Net income: €39.2m (down 37% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 5% per year.
Reported Earnings • Nov 21Third quarter 2020 earnings released: EPS €1.45Third quarter 2020 results: Revenue: €32.5m (down 52% from 3Q 2019). Net income: €39.2m (down 37% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 6% per year.
Is New 90 Day High Low • Oct 29New 90-day low: €117The company is down 4.0% from its price of €122 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the REITs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €136 per share.
Is New 90 Day High Low • Oct 05New 90-day high: €129The company is up 5.0% from its price of €123 on 07 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the REITs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €135 per share.
Is New 90 Day High Low • Sep 20New 90-day high: €128The company is up 2.0% from its price of €126 on 22 June 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €133 per share.